UNITY Biotechnology to host in-person and virtual Ophthalmology Day

(Image credit: AdobeStock/Rawpixel.com)

UNITY Biotechnology, Inc. is set to host an in-person and virtual event for investors and analysts on Tuesday, October 15, 2024.

The event will focus on UNITY’s ongoing Phase 2b ASPIRE study, which is evaluating foselutoclax (UBX1325) head-to-head against aflibercept in diabetic macular edema (DME). Along with the data being presented during the scheduled event, the 24-week safety and efficacy data are expected in the first quarter of 2025. Further reporting is set to include 36-week data, which are expected in the second quarter of 2025.

According to a press release from the company, the agenda for the event is as follows:

Day: Tuesday, October 15, 2024

Time: 8:00 am until 9:30 am ET

Location: Park Terrace Hotel, New York, NY (with simultaneous webcast)

Registration and Webcast: https://lifescievents.com/event/unitybiotechnology/

• Welcome and Introductions: Anirvan Ghosh, PhD, Chief Executive Officer, UNITY Biotechnology
• Senolytic Therapeutic Hypothesis: Mike Sapieha, PhD, Chief Scientist, UNITY Biotechnology
• UBX1325 Clinical Development Plan – BEHOLD and ASPIRE studies in DME: Robert Bhisitkul, MD, PhD, UCSF School of Medicine
• Retina Expert Roundtable:
  • Arshad Khanani, MD, MA, FASRS, Sierra Eye Associates, University of Nevada Reno School of Medicine
  • Dante Pieramici, M.D., California Retina Consultants
  • Alicia Tozier, Chief Strategy Officer, UNITY Biotechnology
• Live Q&A

Archived replays will be available for 90 days following the event on the company's website.

Reference:

1. UNITY Biotechnology to Host In-Person Ophthalmology Day in New York on Tuesday, October 15, 2024. UNITY Biotechnology, Inc. September 24, 2024. Accessed October 8, 2024. https://www.globenewswire.com/news-release/2024/09/24/2952129/0/en/UNITY-Biotechnology-to-Host-In-Person-Ophthalmology-Day-in-New-York-on-Tuesday-October-15-2024.html